1887

Abstract

My research interests focus on identifying novel compounds that can disrupt key phenotypes associated with antibiotic resistance such as biofilm formation and motility in the pathogens and . To this end we have developed a range of screens and assays to facilitate compound identification and mechanism of action profiling in these pathogens. These include: Antibiotic Resistance Inhibitor Screens, Biofilm Inhibition Screens, Biofilm Disruption Screens, Signalling Pathway Specific Biosensor Screens , Mechanism of Action Assays, Resistance Development Screens, Antibiotic Resistance Inhibitor Screens, biofilm and pathogenicity models to validate lead compounds and perform toxicity profiling.

Future goals include being part of a collaborative multidisciplinary drug discovery network that has access to diverse and bespoke extract/compound collections and the expertise to identify the bioactive leads, characterise their mechanism of action and ultimately take them forward to clinical trials. Further to this the goal is to target national and international funding opportunities that will facilitate taking active compounds right through the drug discovery pipeline from the bench to the bedside. I am hoping to identify collaborators across all aspects of drugs discovery, particularly collaborators with: Access to compound or extract collections, Expertise in compound identification ,Clinical trial expertise.

Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.amrmeds2019.po0003
2019-12-01
2020-01-24
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.amrmeds2019.po0003
Loading

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error